M. Zabihzadeh, Z. Ghahremani, S. Hoseini, H. Shahbazian, M. H. Ghahfarokhi
{"title":"Effect of lung inhomogeneity on dose distribution during radiotherapy of patient with lung cancer","authors":"M. Zabihzadeh, Z. Ghahremani, S. Hoseini, H. Shahbazian, M. H. Ghahfarokhi","doi":"10.18869/ACADPUB.IJRR.18.3.579","DOIUrl":null,"url":null,"abstract":"Background: Presence of inhomogeneities such as lung tissue with low density can perturbs the dose distribution in the path of therapeutic photon beam and causes undesired cold or hot spots. The aim of this study was to investigate the effect of lung tissue inhomogeneities on dose distribution in thorax irradiation. Materials and Methods: The Monte Carlo simulation (MC) code of EGSnrc-based BEAMnrc was used to calculate dose distribution for 6 MVSiemens Primus linear accelerator (Linac) in a homogenous phantom. Dose perturbation and inhomogeneity corrected factors (ICFs) were calculated due to implementation of lung tissue depended to the lung density and field size. Results: The maximum increased dose in lung tissue with lung density of 0.5 and 0.25gr/cm was 15.9%, 16.2%, 15.6%, 23.8 %, 24.8% and 25.0% for 6 × 6, 10 × 10 and 20 × 20 cm field sizes, respectively. The maximum ICF for these field sizes was 1.16 and 1.25 for lung density of 0.5 and 0.25gr/cm, respectively. The maximum dose reduction in lung tissue with density of 0.25 and 0.5gr/cm was 19.5% and 4.2 %, and the related ICF was estimated 0.84 and 0.95, respectively. Conclusion: Involvement of lung tissue in the path of irradiation perturbs the dose distribution which is dependent to the lung density and field size. The ICFs resulted from our MC model could be useful to accurately calculate the dose distribution in radiotherapy of lung abnormalities.","PeriodicalId":14498,"journal":{"name":"Iranian Journal of Radiation Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Radiation Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18869/ACADPUB.IJRR.18.3.579","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Health Professions","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Presence of inhomogeneities such as lung tissue with low density can perturbs the dose distribution in the path of therapeutic photon beam and causes undesired cold or hot spots. The aim of this study was to investigate the effect of lung tissue inhomogeneities on dose distribution in thorax irradiation. Materials and Methods: The Monte Carlo simulation (MC) code of EGSnrc-based BEAMnrc was used to calculate dose distribution for 6 MVSiemens Primus linear accelerator (Linac) in a homogenous phantom. Dose perturbation and inhomogeneity corrected factors (ICFs) were calculated due to implementation of lung tissue depended to the lung density and field size. Results: The maximum increased dose in lung tissue with lung density of 0.5 and 0.25gr/cm was 15.9%, 16.2%, 15.6%, 23.8 %, 24.8% and 25.0% for 6 × 6, 10 × 10 and 20 × 20 cm field sizes, respectively. The maximum ICF for these field sizes was 1.16 and 1.25 for lung density of 0.5 and 0.25gr/cm, respectively. The maximum dose reduction in lung tissue with density of 0.25 and 0.5gr/cm was 19.5% and 4.2 %, and the related ICF was estimated 0.84 and 0.95, respectively. Conclusion: Involvement of lung tissue in the path of irradiation perturbs the dose distribution which is dependent to the lung density and field size. The ICFs resulted from our MC model could be useful to accurately calculate the dose distribution in radiotherapy of lung abnormalities.
期刊介绍:
Iranian Journal of Radiation Research (IJRR) publishes original scientific research and clinical investigations related to radiation oncology, radiation biology, and Medical and health physics. The clinical studies submitted for publication include experimental studies of combined modality treatment, especially chemoradiotherapy approaches, and relevant innovations in hyperthermia, brachytherapy, high LET irradiation, nuclear medicine, dosimetry, tumor imaging, radiation treatment planning, radiosensitizers, and radioprotectors. All manuscripts must pass stringent peer-review and only papers that are rated of high scientific quality are accepted.